Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy
- Conditions
- Kidney Replacement Disorder
- Registration Number
- NCT01276392
- Lead Sponsor
- Klinik für Anästhesiologie
- Brief Summary
Actual clinical practice predominantly makes use of heparin (systemically) or citrate regionally as anticoagulation in the extracorporeal circulation for renal replacement therapy. We aim to find out if different anticoagulation strategies may lead to different levels of platelet activation and whole blood coagulation. Regarding coagulation activation, it remains uncertain if there is an advantage for one of these methods. However, it is of major interest to minimize the risk of any additional clotting activation via extracorporeal circulation in these usually critically ill patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Age > 18 years, acute renal failure with need for continuous veno-venous renal replacement therapy
- Age < 18 years, pregnancy, contraindications for one of the two anticoagulation methods, missing informed consent or disagreement in the progress of the study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Filter life time of continuous renal replacement therapy Individual time point, standardized Filter life time measured in hours of duration of continuos renal replacement therapy, filter life time end, when system clotts.
- Secondary Outcome Measures
Name Time Method Activation of coagulation beginning of hemodialysis, 1,2,4,12,24,28,72 hours after start of hemodialysis blood samples for multiplate, rotem and systemic coagulation paramters
Trial Locations
- Locations (1)
Interdisciplinary Operative Intensive Care Unit, University Hospital Duesseldorf
🇩🇪Duesseldorf, NRW, Germany